News / Korea / yonhap_finance
Hyundai Pharm Shares Rally Over 5% on Abortion Pill Launch Hopes
Health Technology · Pharmaceuticals: Major · yonhap_finance · 2026-09-17
004310
Hyundai Pharm shares rose as the government announced plans to introduce abortion pills by the first quarter of next year.
What Happened
Market Reaction: Hyundai Pharm shares closed 5.32% higher at 10,500 KRW following news that the government aims to introduce the abortion pill 'Mifegymiso' by the first quarter of next year. Investor sentiment was bolstered by the government's clear timeline for the drug's domestic launch.
Government Policy: Shin Joon-soo, head of the Drug Safety Bureau at the Ministry of Food and Drug Safety, stated that the goal is to complete the introduction by Q1 next year, provided that all necessary procedures are followed. The regulatory review process is currently in its final stages, including risk management plan assessments.
Company Involvement: Hyundai Pharm holds the exclusive domestic distribution rights for Mifegymiso, having signed a contract with the UK-based pharmaceutical firm Linepharma International. The company has been seeking regulatory approval since 2021, and the government's recent announcement has raised expectations for a successful outcome.
Future Outlook: Analysts suggest that the government's proactive stance has significantly increased expectations for the drug's approval. The final regulatory decision and the actual launch date remain critical factors that will influence Hyundai Pharm's stock performance moving forward.